市場調查報告書
商品編碼
391496

視網膜胚細胞瘤治療的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Retinoblastoma Treatment Market - Growth, Trends, and Forecast (2019 - 2024)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球硬薄膜視網膜胚細胞瘤治療市場在2018年估算為22億9,713萬美元,至2024年預計將以4.56%的年複合成長率發展,成長到30億178萬美元。市場成長要素有復發的可能性和認知度的高漲。

本報告提供全球視網膜胚細胞瘤治療市場調查,市場概要,各治療方法、種類、分期、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 寬解和復發的可能性
    • 認知度的高漲
  • 市場阻礙因素
    • 患者數很少
    • 視網膜胚細胞瘤手術的副作用
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場細分化

  • 各治療法
    • 手術
    • 放射線治療
    • 雷射治療
    • 冷凍治療
    • 溫熱療法
    • 化療
    • 眼科動脈注射化療
    • 大量化療 & 幹細胞移植
  • 各類型
    • 非遺傳性視網膜胚細胞瘤
    • 遺傳性視網膜胚細胞瘤
  • 各病期
    • 眼球內
    • 眼球外
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Baxter International Inc.
    • Bristol-Myers Squibb Company
    • Cadila Pharmaceuticals
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.

第7章 市場機會及未來趨勢

目錄
Product Code: 50157

Market Overview

Global Retinoblastoma Treatment market was valued at USD 2297.13 million in 2018, and is estimated to be valued at USD 3001.78 million in 2024, witnessing a CAGR of 4.56%. certain factors that are driving the market growth include remission and the chance of recurrence, and increasing public awareness.

Recurrent retinoblastoma occurs, when cancer comes back after it has been treated and diagnosed. Both extraocular and intraocular retinoblastoma might have probable chances of remittance.

Generally, the likelihood of relapse and formation of secondary tumors increases with the genetic nature of the disease. Patients with non-hereditary or sporadic retinoblastoma are not as susceptible to relapse, as hereditary ones. Although, the cure rate for retinoblastoma is quite high, the exact cure rate is dependent on the extent of the disease and chances of recurrence. The increasing number of treatment procedures drive the retinoblastoma treatment market.

In addition, improving awareness about retinoblastoma is a worthwhile goal, and any eye complaint merits careful attention from all nursing and medical personnel. Improving awareness regarding retinoblastoma is especially important in developing countries, as the incidences of eye cancer are increasing, and many children die undiagnosed or have advanced disease at presentation, due to delay in referral to an oncology centre. Retinoblastoma educational and public awareness campaigns have been shown to increase referrals, decrease rates of advanced disease, and improve outcomes in low and middle-income countries.

However, side effects of retinoblastoma surgery, radiation therapy to the head and certain chemotherapy drugs, such as cisplatin and carboplatin (Paraplatin, Paraplatin AQ), may cause hearing loss when they are given to very young children. The other eye problems include difficulty in judging distance between objects and difficulty seeing to the side (peripheral vision). Eye problems can also lead to changes in balance.

Scope of the Report

Retinoblastoma is the most common cancer among children, which starts in the retina. It generally develops before the age of 5. One out of three children with retinoblastoma develops cancer in both eyes. The most common symptom of retinoblastoma is a visible whiteness in the pupil, called cat's eye reflex or leukocoria.

Key Market Trends

Non-hereditary Retinoblastoma is Expected to hold its Highest Market Share in the Retinoblastoma Type Segment

In the Retinoblastoma type segment of the Retinoblastoma treatment market, the non-hereditary retinoblastoma (NHR) is expected to have the largest market size and is likely to witness a CAGR of 3.82% in the forecast period.

Non-hereditary retinoblastoma (NHR), also known as sporadic retinoblastoma, is the more prevalent form of retinoblastoma. According to the American Cancer Society, 67% of reported cases (in the United States) of retinoblastoma in pediatrics are non-hereditary or sporadic.

The NHR is mostly a pediatric disease, and according to the American Cancer Society, the survival rates post diagnosis is approximately 90%. According to the Union for International Cancer Control, the average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately one in 14,000 - 18,000 live births).

The market for NHR is expected to grow tremendously over the forecast period, primarily due to the higher incidence rate, when compared to hereditary retinoblastoma. Additionally, factors, like high survival rates post diagnosis in developed regions, like the United States, are likely to add to the global market growth.

Asia-Pacific Dominates the Market and Expected to do Same in the Forecast Period

Asia-Pacific currently dominates the market for Retinoblastoma Treatment and is expected to continue its strong hold for a few more years. This region is expected to increase its market share in the future owing to the fact that, retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.

According to the United Nations Survey in 2016, China was only second to that in India, in the prevalence of Rb in APAC countries. Similarly, according to the Japanese Journal of Ophthalmology, in 2018, the average occurrence frequency for retinoblastoma was 1:16,823 births/year and at diagnosis, 89.0% of the patients were aged younger than 3 years and 41.0% were aged younger than 1 year.

Furthermore, in countries like India, current treatment modalities of systemic chemotherapy and focal treatment have contributed significantly to disability limitation and patient survival and there is less knowledge on the genetics of the retinoblastoma gene and its protein, and there is potential for developing targeted molecular therapies.

Competitive Landscape

The Retinoblastoma Treatment market is moderately competitive and consists of a considerable number of major players. Companies like B Baxter International Inc., GlaxoSmithKline, Pfizer Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, Merck & Co., Cadila Pharmaceuticals, and Teva Pharmaceutical, among others, are expected to hold the substantial market share in the Retinoblastoma Treatment market.

Various developments have recently been taking place in the market. For example, in June 2018, GSK completed the Consumer Healthcare buyout of Novartis.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Remission and the Chance of Recurrence
    • 4.2.2 Increasing Public Awareness
  • 4.3 Market Restraints
    • 4.3.1 Small Patient Pool
    • 4.3.2 Side Effects of Retinoblastoma Surgery
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Surgery
    • 5.1.2 Radiation therapy
    • 5.1.3 Laser Therapy (Photocoagulation)
    • 5.1.4 Cryotherapy
    • 5.1.5 Thermotherapy
    • 5.1.6 Chemotherapy
      • 5.1.6.1 Carboplatin
      • 5.1.6.2 Cisplatin
      • 5.1.6.3 Vincristine
      • 5.1.6.4 Etoposide
      • 5.1.6.5 Cyclophosphamide
      • 5.1.6.6 Topotecan
      • 5.1.6.7 Doxorubicin
      • 5.1.6.8 Cyclosporine
      • 5.1.6.9 Melphalan
    • 5.1.7 Opthalmic Artery Infusion Chemotherapy
    • 5.1.8 High-dose Chemotherapy and Stem Cell Transplant
  • 5.2 By Type of Retinoblastoma
    • 5.2.1 Non-hereditary Retinoblastoma
    • 5.2.2 Hereditary Retinoblastoma
  • 5.3 By Type of Staging
    • 5.3.1 Intraocular Retinoblastoma
    • 5.3.2 Extraocular Retinoblastoma
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Cadila Pharmaceuticals
    • 6.1.4 GlaxoSmithKline plc
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Merck & Co.
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS